Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Annals of the Rheumatic Diseases
Jul 1, 2017
Stanley B CohenJürgen Wollenhaupt
PMID: 28143815
Get paper from
Abstract
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. Data were pooled for a...read more
Mentioned in this Paper
Rheumatoid Arthritis
Malignant Neoplasms
Malignant Neoplasm of Skin
Clinical Trials
Communicable Diseases
Herpes Zoster Disease
Opportunistic Infections
Piperidines
Pyrimidines
Pyrroles
10
2
1
118
Paper Details
References
- References48
- Citations43
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis
Arthritis & RheumatologyNovember 1, 2014Stanley B CohenRichard J Riese
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
Arthritis and RheumatismJuly 1, 2009Joel M KremerSamuel H Zwillich1621Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study
Arthritis and RheumatismSeptember 1, 2007Frederick J Wolfe, Kaleb D Michaud21451Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Arthritis and RheumatismFebruary 1, 2004Frederick J WolfeKathy Urbansky110
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
The New England Journal of MedicineAugust 9, 2012Roy M FleischmannORAL Solo Investigators5434131
Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
Pharmacoepidemiology and Drug SafetyMay 1, 2012Sengwee TohLisa J Herrinton
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
Arthritis Research & TherapyApril 6, 2015Joel M KremerJohn Dudley Isaacs1156Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
Arthritis and RheumatismMarch 1, 2013Désirée M F M van der HeijdeORAL Scan Investigators1821188
Risk of malignancy among patients with rheumatic conditions
International Journal of Cancer. Journal International Du CancerNovember 1, 2000E.J. ThomasGary John MacfarlaneSystematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Arthritis Research & TherapyDecember 15, 2015Vibeke StrandJuan Jesus Gomez-Reino18287
12345
- References48
- Citations43
Tofacitinib: A Review in Rheumatoid Arthritis
DrugsNovember 16, 2017Sohita Dhillon1152Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study
Annals of the Rheumatic DiseasesJuly 1, 2017Yi-Ming ChenTsu-Yi Hsieh14218
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Pediatric Rheumatology Online JournalDecember 28, 2017Nicolino RupertoPediatric Rheumatology Collaborative Study Group (PRCSG)3132Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre
Annals of the Rheumatic DiseasesApril 22, 2019Hanxiao YouXiao-Feng Zeng137
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
GutJune 23, 2019Marjorie C ArgolloLaurent Peyrin-Biroulet5127
A Practical Guide to the Safety and Monitoring of New IBD Therapies
Inflammatory Bowel DiseasesOctober 13, 2018Benjamin H Click, Miguel D Regueiro4024
Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials
Expert Opinion on Investigational DrugsNovember 19, 2019Jing- WuChanghai Ding
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review
ImmunotherapyApril 9, 2019Jehanya JegatheeswaranJanet E Pope
JAK/STAT inhibitors for the treatment of atopic dermatitis
The Journal of Dermatological TreatmentJanuary 31, 2019Maria Alexandra Rodrigues, Tiago Torres
Tofacitinib for the treatment of rheumatoid arthritis: an update
Expert Review of Clinical ImmunologyApril 19, 2019Kunihiro Yamaoka
12345
Related Papers
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
Arthritis Research & TherapyJanuary 28, 2016
Hisashi YamanakaSamuel H Zwillich
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Annals of the Rheumatic DiseasesAugust 16, 2015
Christina Charles-SchoemanRoy M Fleischmann
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Abstract
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. Data were pooled for a...read more
Mentioned in this Paper
Rheumatoid Arthritis
Malignant Neoplasms
Malignant Neoplasm of Skin
Clinical Trials
Communicable Diseases
10
2
1
118
Related Papers
Paper Details
References
- References48
- Citations43
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis
Arthritis & RheumatologyNovember 1, 2014Stanley B CohenRichard J RieseThe safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
Arthritis and RheumatismJuly 1, 2009Joel M KremerSamuel H Zwillich1621Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study
Arthritis and RheumatismSeptember 1, 2007Frederick J Wolfe, Kaleb D Michaud21451Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Arthritis and RheumatismFebruary 1, 2004Frederick J WolfeKathy Urbansky110Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
The New England Journal of MedicineAugust 9, 2012Roy M FleischmannORAL Solo Investigators5434131Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
Pharmacoepidemiology and Drug SafetyMay 1, 2012Sengwee TohLisa J HerrintonEvaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
Arthritis Research & TherapyApril 6, 2015Joel M KremerJohn Dudley Isaacs1156Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study
Arthritis and RheumatismMarch 1, 2013Désirée M F M van der HeijdeORAL Scan Investigators1821188Risk of malignancy among patients with rheumatic conditions
International Journal of Cancer. Journal International Du CancerNovember 1, 2000E.J. ThomasGary John MacfarlaneSystematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Arthritis Research & TherapyDecember 15, 2015Vibeke StrandJuan Jesus Gomez-Reino18287
12345
- References48
- Citations43
Tofacitinib: A Review in Rheumatoid Arthritis
DrugsNovember 16, 2017Sohita Dhillon1152Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study
Annals of the Rheumatic DiseasesJuly 1, 2017Yi-Ming ChenTsu-Yi Hsieh14218Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Pediatric Rheumatology Online JournalDecember 28, 2017Nicolino RupertoPediatric Rheumatology Collaborative Study Group (PRCSG)3132Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre
Annals of the Rheumatic DiseasesApril 22, 2019Hanxiao YouXiao-Feng Zeng137JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
GutJune 23, 2019Marjorie C ArgolloLaurent Peyrin-Biroulet5127A Practical Guide to the Safety and Monitoring of New IBD Therapies
Inflammatory Bowel DiseasesOctober 13, 2018Benjamin H Click, Miguel D Regueiro4024Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials
Expert Opinion on Investigational DrugsNovember 19, 2019Jing- WuChanghai DingComparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review
ImmunotherapyApril 9, 2019Jehanya JegatheeswaranJanet E PopeJAK/STAT inhibitors for the treatment of atopic dermatitis
The Journal of Dermatological TreatmentJanuary 31, 2019Maria Alexandra Rodrigues, Tiago TorresTofacitinib for the treatment of rheumatoid arthritis: an update
Expert Review of Clinical ImmunologyApril 19, 2019Kunihiro Yamaoka
12345
Get paper from